Kaichuan Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kaichuan Zhu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Jochen Herms
Institute of Neuropathology, LMU Medizin, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany
4 shared publications - Gerhard Rammes
Department of Anesthesiology and Intensive Care, Klinikum Rechts der Isar, Ismaningerstraße 22, 81675 Munich, Germany
3 shared publications - Xianyuan Xiang
Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
3 shared publications Chris G. Parsons
Non-Clinical Science, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
2 shared publicationsFranziska Seeser
Department of Anaesthesiology, Technische Universität München, Munich, Germany
2 shared publicationsGerhard Rammes
Department of Anaesthesiology and Intensive Care Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 Munich, Germany
2 shared publications
Latest Publications
- Open Access
TREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages
Triggering receptor expressed on myeloid cell 2 (TREM2), a myeloid cell‐specific signaling molecule, controls essential functions of microglia and impacts on the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. TREM2 is also highly expressed in tumor‐associated macrophages in different types of cancer. Here, we studied whether TREM2 influences glioma progression. We found a gender‐dependent effect of glioma growth in wild‐type (WT) animals injected with GL261‐EGFP glioma cells. Most importantly, TREM2 promotes glioma progression in male but not female animals. The accumulation of glioma‐associated microglia/macrophages (GAMs) and CD31+ blood vessel density is reduced in male TREM2‐deficient mice. A transcriptomic analysis of glioma tissue revealed that TREM2 deficiency suppresses immune‐related genes. In an organotypic slice model devoid of functional vascularization and immune components from periphery, the tumor size was not affected by TREM2‐deficiency. In human resection samples from glioblastoma, TREM2 is upregulated in GAMs. Based on the Cancer Genome Atlas Program (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases, the TREM2 expression levels were negatively correlated with survival. Thus, the TREM2‐dependent crosstalk between GAMs and the vasculature formation promotes glioma growth.
Open AccessTREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages
Triggering receptor expressed on myeloid cell 2 (TREM2), a myeloid cell‐specific signaling molecule, controls essential functions of microglia and impacts on the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. TREM2 is also highly expressed in tumor‐associated macrophages in different types of cancer. Here, we studied whether TREM2 influences glioma progression. We found a gender‐dependent effect of glioma growth in wild‐type (WT) animals injected with GL261‐EGFP glioma cells. Most importantly, TREM2 promotes glioma progression in male but not female animals. The accumulation of glioma‐associated microglia/macrophages (GAMs) and CD31+ blood vessel density is reduced in male TREM2‐deficient mice. A transcriptomic analysis of glioma tissue revealed that TREM2 deficiency suppresses immune‐related genes. In an organotypic slice model devoid of functional vascularization and immune components from periphery, the tumor size was not affected by TREM2‐deficiency. In human resection samples from glioblastoma, TREM2 is upregulated in GAMs. Based on the Cancer Genome Atlas Program (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases, the TREM2 expression levels were negatively correlated with survival. Thus, the TREM2‐dependent crosstalk between GAMs and the vasculature formation promotes glioma growth.
- Open Access
- 4 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 912
The Anaesthetics Isoflurane and Xenon Reverse the Synaptotoxic Effects of Aβ1–42 on Megf10-Dependent Astrocytic Synapse Elimination and Spine Density in Ex Vivo Hippocampal Brain Slices
It has been hypothesised that inhalational anaesthetics such as isoflurane (Iso) may trigger the pathogenesis of Alzheimer’s disease (AD), while the gaseous anaesthetic xenon (Xe) exhibits many features of a putative neuroprotective agent. Loss of synapses is regarded as one key cause of dementia in AD. Multiple EGF-like domains 10 (MEGF10) is one of the phagocytic receptors which assists the elimination of synapses by astrocytes. Here, we investigated how β-amyloid peptide 1–42 (Aβ1–42), Iso and Xe interact with MEGF10-dependent synapse elimination. Murine cultured astrocytes as well as cortical and hippocampal ex vivo brain slices were treated with either Aβ1–42, Iso or Xe and the combination of Aβ1–42 with either Iso or Xe. We quantified MEGF10 expression in astrocytes and dendritic spine density (DSD) in slices. In brain slices of wild type and AAV-induced MEGF10 knock-down mice, antibodies against astrocytes (GFAP), pre- (synaptophysin) and postsynaptic (PSD95) components were used for co-localization analyses by means of immunofluorescence-imaging and 3D rendering techniques. Aβ1–42 elevated pre- and postsynaptic components inside astrocytes and decreased DSD. The combined application with either Iso or Xe reversed these effects. In the presence of Aβ1–42 both anaesthetics decreased MEGF10 expression. AAV-induced knock-down of MEGF10 reduced the pre- and postsynaptic marker inside astrocytes. The presented data suggest Iso and Xe are able to reverse the Aβ1–42-induced enhancement of synaptic elimination in ex vivo hippocampal brain slices, presumably through MEGF10 downregulation.
- 4 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 912
Open AccessThe Anaesthetics Isoflurane and Xenon Reverse the Synaptotoxic Effects of Aβ1–42 on Megf10-Dependent Astrocytic Synapse Elimination and Spine Density in Ex Vivo Hippocampal Brain Slices
It has been hypothesised that inhalational anaesthetics such as isoflurane (Iso) may trigger the pathogenesis of Alzheimer’s disease (AD), while the gaseous anaesthetic xenon (Xe) exhibits many features of a putative neuroprotective agent. Loss of synapses is regarded as one key cause of dementia in AD. Multiple EGF-like domains 10 (MEGF10) is one of the phagocytic receptors which assists the elimination of synapses by astrocytes. Here, we investigated how β-amyloid peptide 1–42 (Aβ1–42), Iso and Xe interact with MEGF10-dependent synapse elimination. Murine cultured astrocytes as well as cortical and hippocampal ex vivo brain slices were treated with either Aβ1–42, Iso or Xe and the combination of Aβ1–42 with either Iso or Xe. We quantified MEGF10 expression in astrocytes and dendritic spine density (DSD) in slices. In brain slices of wild type and AAV-induced MEGF10 knock-down mice, antibodies against astrocytes (GFAP), pre- (synaptophysin) and postsynaptic (PSD95) components were used for co-localization analyses by means of immunofluorescence-imaging and 3D rendering techniques. Aβ1–42 elevated pre- and postsynaptic components inside astrocytes and decreased DSD. The combined application with either Iso or Xe reversed these effects. In the presence of Aβ1–42 both anaesthetics decreased MEGF10 expression. AAV-induced knock-down of MEGF10 reduced the pre- and postsynaptic marker inside astrocytes. The presented data suggest Iso and Xe are able to reverse the Aβ1–42-induced enhancement of synaptic elimination in ex vivo hippocampal brain slices, presumably through MEGF10 downregulation.
- 1 February 2019
- Published by Elsevier in Behavioural Brain Research
- Vol. 359, 408-417
Cognitive decline in Tg2576 mice shows sex-specific differences and correlates with cerebral amyloid-beta
- 1 February 2019
- Published by Elsevier in Behavioural Brain Research
- Vol. 359, 408-417
Cognitive decline in Tg2576 mice shows sex-specific differences and correlates with cerebral amyloid-beta
- 1 October 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 84 (7) , 478-487
Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function
- 1 October 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 84 (7) , 478-487
Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function
- Open Access
- 6 September 2018
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 13 (1) , 1-14
The Trem2 R47H Alzheimer’s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans
The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer’s disease. Mouse models accurately reproducing phenotypes observed in Alzheimer’ disease patients carrying the R47H coding variant are required to understand the TREM2 related dysfunctions responsible for the enhanced risk for late onset Alzheimer’s disease. A CRISPR/Cas9-assisted gene targeting strategy was used to generate Trem2 R47H knock-in mice. Trem2 mRNA and protein levels as well as Trem2 splicing patterns were assessed in these mice, in iPSC-derived human microglia-like cells, and in human brains from Alzheimer’s patients carrying the TREM2 R47H risk factor. Two independent Trem2 R47H knock-in mouse models show reduced Trem2 mRNA and protein production. In both mouse models Trem2 haploinsufficiency was due to atypical splicing of mouse Trem2 R47H, which introduced a premature stop codon. Cellular splicing assays using minigene constructs demonstrate that the R47H variant induced abnormal splicing only occurs in mice but not in humans. TREM2 mRNA levels and splicing patterns were both normal in iPSC-derived human microglia-like cells and patient brains with the TREM2 R47H variant. The Trem2 R47H variant activates a cryptic splice site that generates miss-spliced transcripts leading to Trem2 haploinsufficiency only in mice but not in humans. Since Trem2 R47H related phenotypes are mouse specific and do not occur in humans, humanized TREM2 R47H knock-in mice should be generated to study the cellular consequences caused by the human TREM2 R47H coding variant. Currently described phenotypes of Trem2 R47H knock-in mice can therefore not be translated to humans.
- 6 September 2018
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 13 (1) , 1-14
Open AccessThe Trem2 R47H Alzheimer’s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans
The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer’s disease. Mouse models accurately reproducing phenotypes observed in Alzheimer’ disease patients carrying the R47H coding variant are required to understand the TREM2 related dysfunctions responsible for the enhanced risk for late onset Alzheimer’s disease. A CRISPR/Cas9-assisted gene targeting strategy was used to generate Trem2 R47H knock-in mice. Trem2 mRNA and protein levels as well as Trem2 splicing patterns were assessed in these mice, in iPSC-derived human microglia-like cells, and in human brains from Alzheimer’s patients carrying the TREM2 R47H risk factor. Two independent Trem2 R47H knock-in mouse models show reduced Trem2 mRNA and protein production. In both mouse models Trem2 haploinsufficiency was due to atypical splicing of mouse Trem2 R47H, which introduced a premature stop codon. Cellular splicing assays using minigene constructs demonstrate that the R47H variant induced abnormal splicing only occurs in mice but not in humans. TREM2 mRNA levels and splicing patterns were both normal in iPSC-derived human microglia-like cells and patient brains with the TREM2 R47H variant. The Trem2 R47H variant activates a cryptic splice site that generates miss-spliced transcripts leading to Trem2 haploinsufficiency only in mice but not in humans. Since Trem2 R47H related phenotypes are mouse specific and do not occur in humans, humanized TREM2 R47H knock-in mice should be generated to study the cellular consequences caused by the human TREM2 R47H coding variant. Currently described phenotypes of Trem2 R47H knock-in mice can therefore not be translated to humans.
- 1 September 2018
- Published by Elsevier in Neuropharmacology
- Vol. 140, 184-192
The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (Aβ) species on long-term potentiation (LTP)
- 1 September 2018
- Published by Elsevier in Neuropharmacology
- Vol. 140, 184-192
The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (Aβ) species on long-term potentiation (LTP)
- Open Access
- 1 March 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 83 (5) , 428-437
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6
- 1 March 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 83 (5) , 428-437
Open AccessBeta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6
- Open Access
- 29 August 2016
- Published by Springer Nature in The EMBO Journal
- Vol. 35 (20) , 2213-2222
Amyloid precursor protein maintains constitutive and adaptive plasticity of dendritic spines in adult brain by regulating D‐serine homeostasis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 29 August 2016
- Published by Springer Nature in The EMBO Journal
- Vol. 35 (20) , 2213-2222
Open AccessAmyloid precursor protein maintains constitutive and adaptive plasticity of dendritic spines in adult brain by regulating D‐serine homeostasis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.